作者
Saskia Trump, Soeren Lukassen, Markus S Anker, Robert Lorenz Chua, Johannes Liebig, Loreen Thürmann, Victor Max Corman, Marco Binder, Jennifer Loske, Christina Klasa, Teresa Krieger, Bianca P Hennig, Marey Messingschlager, Fabian Pott, Julia Kazmierski, Sven Twardziok, Jan Philipp Albrecht, Jürgen Eils, Sara Hadzibegovic, Alessia Lena, Bettina Heidecker, Thore Bürgel, Jakob Steinfeldt, Christine Goffinet, Florian Kurth, Martin Witzenrath, Maria Theresa Völker, Sarah Dorothea Müller, Uwe Gerd Liebert, Naveed Ishaque, Lars Kaderali, Leif-Erik Sander, Christian Drosten, Sven Laudi, Roland Eils, Christian Conrad, Ulf Landmesser, Irina Lehmann
发表日期
2021/6
期刊
Nature biotechnology
卷号
39
期号
6
页码范围
705-716
出版商
Nature Publishing Group US
简介
In coronavirus disease 2019 (COVID-19), hypertension and cardiovascular diseases are major risk factors for critical disease progression. However, the underlying causes and the effects of the main anti-hypertensive therapies—angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs)—remain unclear. Combining clinical data (n = 144) and single-cell sequencing data of airway samples (n = 48) with in vitro experiments, we observed a distinct inflammatory predisposition of immune cells in patients with hypertension that correlated with critical COVID-19 progression. ACEI treatment was associated with dampened COVID-19-related hyperinflammation and with increased cell intrinsic antiviral responses, whereas ARB treatment related to enhanced epithelial–immune cell interactions. Macrophages and neutrophils of patients with hypertension, in particular under ARB …
学术搜索中的文章
S Trump, S Lukassen, MS Anker, RL Chua, J Liebig… - Nature biotechnology, 2021